Literature DB >> 7192052

Fate of therapy failures in adult idiopathic thrombocytopenic purpura.

V J Picozzi, W R Roeske, W P Creger.   

Abstract

Of 38 adult patients with idiopathic thrombocytopenic purpura followed an average of more than 12 years, 15 suffered splenectomy failure or postsplenectomy recurrence of thrombocytopenia. Nine of the 15 also received immunosuppressive agents, and four of the nine failed such therapy. In eight of these 15 treatment failures normal or safe platelet counts were achieved in a subsequent three to 12 year period during which they received no therapy. The frequency of spontaneous recovery of satisfactory platelet levels in adults with idiopathic thrombocytopenic purpura in whom treatment failed may have negative implications for very vigorous or longstanding immunosuppressive therapeutic attempts in certain cases.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7192052     DOI: 10.1016/0002-9343(80)90419-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.

Authors:  Aamer Aleem; Ahmed S Alaskar; Farja Algahtani; Mushtaq Rather; Muhamad Hitham Almahayni; Abdulkarim Al-Momen
Journal:  Int J Hematol       Date:  2010-07-17       Impact factor: 2.490

2.  [Splenectomy in idiopathic thrombocytopenic purpura].

Authors:  H R Rosen; R Heinz; A P Marczell
Journal:  Langenbecks Arch Chir       Date:  1989

3.  Chronic idiopathic thrombocytopenic purpura.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-09

4.  Treatment of refractory chronic idiopathic thrombocytopenic purpura with high dose intravenous immunoglobulin.

Authors:  E Seifried; G Pindur; H Stötter; M Wiesneth; H Rasche; H Heimpel
Journal:  Blut       Date:  1984-06

5.  Prediction of response to splenectomy in patients with idiopathic thrombocytopenic purpura.

Authors:  A Shojaiefard; S A Mousavi; S H Faghihi; S Abdollahzade
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

6.  Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.

Authors:  James B Bussel; Donald M Arnold; Michael A Boxer; Nichola Cooper; Jiri Mayer; Hany Zayed; Sandra Tong; Anne-Marie Duliege
Journal:  Am J Hematol       Date:  2019-03-13       Impact factor: 10.047

7.  Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.

Authors:  Jaime Garcia-Chavez; Abraham Majluf-Cruz; Laura Montiel-Cervantes; Miriam García-Ruiz Esparza; Jorge Vela-Ojeda
Journal:  Ann Hematol       Date:  2007-09-14       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.